Zepbound® providers &
prescriptions in Newark, NJ
Verified Zepbound providers in Newark, NJ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Zepbound provider in New Jersey.
Every entry is checked against the NPI registry and the New Jersey medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Zepbound in Newark.
46 GLP-1 prescribers and 7 local resource types are on record for Newark, plus 2 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm New Jersey’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.
Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]
Community health · CDC
Weight & metabolic health in Newark
Newark, New Jersey has a population of 311,549 people. The adult obesity rate in Newark is an age-adjusted estimate of 35.9%, 8.2 percentage points above the New Jersey state rate of 27.7%. Diagnosed diabetes reaches 15.5% of adults in Newark. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 39.1% of adults in Newark.
- of Newark adults have obesity
- 35.9%
- diagnosed diabetes
- 15.5%
- no regular physical activity
- 39.1%
Age-adjusted estimates for Newark, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Newark.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Newark, NJ, ordered as the registry lists them, never by who pays us.
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
What the trials actually showed.
We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]